Lucas de Breed
Director, Investments - BrightEdge,
American Cancer Society
Dr. de Breed has over 20 years of experience in Oncology as a scientist, strategy consultant, VC and entrepreneur.
Previously, as an Investment Director at INKEF Capital, a leading European VC firm, Lucas led the allocation of $120 million in US and European therapeutics start-ups, served on the respective Boards, and realized a number of exits. At INKEF, he was instrumental in setting the investment strategy, building out the investment team and in expanding assets under management to $600 million. Prior to that Lucas was a Manager at Deallus, a global strategy consulting firm for large biopharma clients, where he led the Oncology business unit and founded the firm’s East Coast office. Lucas is also the Founder of August, developing outcomes-based financial solutions® for high-cost precision medicine. At BrightEdge Lucas oversees the ACS Impact Venture Fund (AIVF), an $80 million evergreen investment structure, and serves (served) on the boards of Modifi Bio (acquired by Merck), Navigating Cancer (acquired by One Oncology), Interius BioTherapeutics, Immunitas Therapeutics, and Alpheus Medical.
Dr. de Breed holds a PhD in Molecular Oncology from University College London and an MBA from Stanford University. He has also co-authored several scientific and industry papers. He is a Director at Quantum Leap Healthcare, a 501c(3)charitable organization integrating high-impact clinical research with patient care to improve and save lives.
Suffix
PhD, MBA
Sessions
-
11-Feb-2025Prioritizing Alternative Funding Sources
)
){kind=logo}
)
){kind=logo}
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}